title: Reply to: Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerations.
authors.affiliation: Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh, UK.
authors.forename: Laetitia
authors.initials: L
authors.lastname: Canini
authors.affiliation: INSERM, IAME, UMR 1137, F-75018 Paris, France.
authors.forename: Jeremie
authors.initials: J
authors.lastname: Guedj
authors.affiliation: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
authors.forename: Alan S
authors.initials: AS
authors.lastname: Perelson
mesh_terms: D003521:Cyclopropanes; D006526:Hepatitis C; D006801:Humans; D054833:Isoindoles; D007769:Lactams; D047029:Lactams, Macrocyclic; D011392:Proline / Q000031:analogs & derivatives; D013449:Sulfonamides
chemical_list: D003521:Cyclopropanes; D054833:Isoindoles; D007769:Lactams; D047029:Lactams, Macrocyclic; D013449:Sulfonamides; C553752:danoprevir; D011392:Proline